Company profile: Arzeda
1.1 - Company Overview
Company description
- Provider of AI-driven protein and enzyme design and manufacturing for pharmaceuticals, industrial chemicals, and food applications. Offers Intelligent Protein Design Technology to create novel proteins; ProSweet enzymes for efficient production of Reb D and Reb M from stevia; and collaborates with Unilever (cleaning), W. L. Gore (materials), Takeda (therapeutic biologics), and AAK (plant-based oils).
Products and services
- Intelligent Protein Design Technology: AI-driven, computational platform that architects novel proteins and enzymes for pharmaceuticals and industrial chemicals by combining computational design with AI
- ProSweet Enzymes: Industrial-grade biocatalysts engineered to efficiently produce Reb D and Reb M from stevia leaf extract, elevating sweetness and purity in natural sweeteners
- Partnership with Takeda: Pharma-focused collaboration using AI-based protein design to optimize protein biologics for therapeutic products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arzeda
Fujifilm Cellular Dynamics
HQ: United States
Website
- Description: Provider of human induced pluripotent stem cell (iPSC)-derived cells for disease and preclinical research, including excitatory neurons, dopaminergic neurons, and GABAergic neurons (KCNT1, SCN1A KO). Offers CDMO services for contract development and cGMP manufacture of clinical-grade human cells, plus toxicity testing, stem cell banking, and cell therapy development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fujifilm Cellular Dynamics company profile →
ProAxsis
HQ: United Kingdom
Website
- Description: Provider of laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers of disease, incorporating patented ProteaseTags smart molecules that selectively trap active proteases and deliver a visual readout in complex biological samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProAxsis company profile →
Atomic Alchemy
HQ: United States
Website
- Description: Provider of radioisotopes for medical, research, exploration, and industrial use, aiming to establish a reliable domestic supply in the U.S. for medical radioisotopes such as molybdenum-99, in a market that currently lacks a dedicated domestic supplier and relies on university research reactors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atomic Alchemy company profile →
Esperite
HQ: The Netherlands
Website
- Description: Provider of healthcare services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Esperite company profile →
Cellzome
HQ: Germany
Website
- Description: Provider of kinase-targeted drugs and oral kinase inhibitor therapeutics for inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma; engaged in discovery, development, and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellzome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arzeda
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arzeda
2.2 - Growth funds investing in similar companies to Arzeda
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arzeda
4.2 - Public trading comparable groups for Arzeda
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →